Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -33.52 Million USD | -109.72% |
| 2022 | 344.84 Million USD | 58.83% |
| 2021 | 217.11 Million USD | 113.51% |
| 2020 | 101.69 Million USD | -47.64% |
| 2019 | 194.22 Million USD | 41.55% |
| 2018 | 137.21 Million USD | 286.02% |
| 2017 | -73.76 Million USD | 14.19% |
| 2016 | -85.95 Million USD | -56.28% |
| 2015 | -55 Million USD | -16.06% |
| 2014 | -47.38 Million USD | 0.86% |
| 2013 | -47.79 Million USD | 27.15% |
| 2012 | -65.61 Million USD | -244.27% |
| 2011 | -19.05 Million USD | -137.18% |
| 2010 | 51.26 Million USD | 17.58% |
| 2009 | 43.59 Million USD | 97.05% |
| 2008 | 22.12 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -21.27 Million USD | 36.55% |
| 2024 Q3 | -2.74 Million USD | 153.5% |
| 2024 Q2 | -12.11 Million USD | 43.07% |
| 2023 FY | -33.52 Million USD | -109.72% |
| 2023 Q1 | 458.93 Million USD | 33.08% |
| 2023 Q3 | -52.66 Million USD | -401.11% |
| 2023 Q2 | 17.49 Million USD | -96.19% |
| 2023 Q4 | -33.52 Million USD | 36.34% |
| 2022 Q3 | 325.97 Million USD | 20.02% |
| 2022 FY | 344.84 Million USD | 58.83% |
| 2022 Q1 | 330.69 Million USD | 52.31% |
| 2022 Q2 | 271.6 Million USD | -17.87% |
| 2022 Q4 | 344.84 Million USD | 5.79% |
| 2021 FY | 217.11 Million USD | 113.51% |
| 2021 Q3 | 196.76 Million USD | 7.67% |
| 2021 Q2 | 182.75 Million USD | 31.55% |
| 2021 Q1 | 138.92 Million USD | 36.62% |
| 2021 Q4 | 217.11 Million USD | 10.34% |
| 2020 Q3 | 209.39 Million USD | 5.42% |
| 2020 FY | 101.69 Million USD | -47.64% |
| 2020 Q1 | 154.26 Million USD | -20.57% |
| 2020 Q2 | 198.62 Million USD | 28.75% |
| 2020 Q4 | 101.69 Million USD | -51.44% |
| 2019 Q2 | 277.4 Million USD | 16.38% |
| 2019 Q1 | 238.35 Million USD | 73.71% |
| 2019 Q3 | 251.53 Million USD | -9.33% |
| 2019 FY | 194.22 Million USD | 41.55% |
| 2019 Q4 | 194.22 Million USD | -22.78% |
| 2018 Q4 | 137.21 Million USD | -32.02% |
| 2018 Q3 | 201.84 Million USD | -29.6% |
| 2018 FY | 137.21 Million USD | 286.02% |
| 2018 Q2 | 286.71 Million USD | 327.71% |
| 2018 Q1 | -125.91 Million USD | -70.7% |
| 2017 Q4 | -73.76 Million USD | -36.68% |
| 2017 Q3 | -53.96 Million USD | 41.01% |
| 2017 Q2 | -91.49 Million USD | -62.54% |
| 2017 Q1 | -56.28 Million USD | 34.51% |
| 2017 FY | -73.76 Million USD | 14.19% |
| 2016 FY | -85.95 Million USD | -56.28% |
| 2016 Q1 | -39.63 Million USD | 27.95% |
| 2016 Q3 | -48.53 Million USD | 10.97% |
| 2016 Q4 | -85.95 Million USD | -77.11% |
| 2016 Q2 | -54.51 Million USD | -37.56% |
| 2015 Q1 | -14.1 Million USD | 70.24% |
| 2015 FY | -55 Million USD | -16.06% |
| 2015 Q4 | -55 Million USD | -10.81% |
| 2015 Q3 | -49.63 Million USD | 18.67% |
| 2015 Q2 | -61.02 Million USD | -332.77% |
| 2014 Q1 | 16.1 Million USD | 133.7% |
| 2014 FY | -47.38 Million USD | 0.86% |
| 2014 Q4 | -47.38 Million USD | -320.0% |
| 2014 Q3 | -11.28 Million USD | -167.5% |
| 2014 Q2 | 16.71 Million USD | 3.78% |
| 2013 Q3 | 37.23 Million USD | 185.52% |
| 2013 Q4 | -47.79 Million USD | -228.39% |
| 2013 Q1 | -49.78 Million USD | 24.13% |
| 2013 FY | -47.79 Million USD | 27.15% |
| 2013 Q2 | -43.53 Million USD | 12.55% |
| 2012 Q2 | -19.43 Million USD | -246.88% |
| 2012 Q3 | 2.19 Million USD | 111.29% |
| 2012 Q4 | -65.61 Million USD | -3090.47% |
| 2012 FY | -65.61 Million USD | -244.27% |
| 2012 Q1 | 13.23 Million USD | 169.42% |
| 2011 FY | -19.05 Million USD | -137.18% |
| 2011 Q3 | 73.03 Million USD | 0.0% |
| 2011 Q4 | -19.05 Million USD | -126.1% |
| 2010 FY | 51.26 Million USD | 17.58% |
| 2010 Q4 | 51.26 Million USD | 3.05% |
| 2010 Q3 | 49.74 Million USD | 0.0% |
| 2009 FY | 43.59 Million USD | 97.05% |
| 2009 Q4 | 43.59 Million USD | 0.0% |
| 2008 FY | 22.12 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 24.87 Million USD | 234.804% |
| Harrow Health, Inc. | 116.41 Million USD | 128.799% |
| Dynavax Technologies Corporation | 106.63 Million USD | 131.441% |
| Biofrontera Inc. | 4.05 Million USD | 926.603% |
| Cronos Group Inc. | -663.32 Million USD | 94.946% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -1230.437% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 105.378% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -130.078% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -546.487% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 31474.989% |
| Radius Health, Inc. | 359.28 Million USD | 109.332% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 17100.745% |
| DURECT Corporation | -7.65 Million USD | -338.032% |
| ProPhase Labs, Inc. | 19.23 Million USD | 274.338% |
| Safety Shot Inc | -2.28 Million USD | -1367.666% |
| Phibro Animal Health Corporation | 454.84 Million USD | 107.371% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -255.546% |
| Alvotech | 1.06 Billion USD | 103.15% |
| Assertio Holdings, Inc. | -32.52 Million USD | -3.068% |
| Rockwell Medical, Inc. | 4.45 Million USD | 852.401% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -114.44% |
| Procaps Group S.A. | 242.93 Million USD | 113.801% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 74.373% |
| SCYNEXIS, Inc. | -19.35 Million USD | -73.266% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -587.451% |
| Viatris Inc. | 17.13 Billion USD | 100.196% |
| OptiNose, Inc. | 58.06 Million USD | 157.74% |
| SIGA Technologies, Inc. | -148.68 Million USD | 77.451% |
| Tilray Brands, Inc. | 158.97 Million USD | 121.089% |
| PetIQ, Inc. | 351.93 Million USD | 109.527% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -114.44% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 118.91% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -427.183% |
| Alimera Sciences, Inc. | 55.3 Million USD | 160.618% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 107.701% |
| Silver Spike Investment Corp. | -32.61 Million USD | -2.807% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -2152.066% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 323.32% |
| Journey Medical Corporation | -9.7 Million USD | -245.319% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -562.539% |
| Alpha Teknova, Inc. | 1.97 Million USD | 1798.43% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -596.448% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 127.504% |
| PainReform Ltd. | -7.95 Million USD | -321.723% |
| Cosmos Health Inc. | 8.59 Million USD | 490.268% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 895.044% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 1011.555% |
| Embecta Corp. | 1.31 Billion USD | 102.555% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -1055.534% |
| Talphera, Inc. | -5.72 Million USD | -486.034% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 107.748% |
| Incannex Healthcare Limited | -5.48 Million USD | -511.249% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -308.195% |
| Shineco, Inc. | 29.29 Million USD | 214.464% |
| Procaps Group, S.A. | 242.93 Million USD | 113.801% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 135.589% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 144.732% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 65.332% |
| Alvotech | 1.06 Billion USD | 103.15% |
| Hempacco Co., Inc. | 13.61 Million USD | 346.256% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 569.237% |
| Bright Green Corporation | 1.84 Million USD | 1920.414% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 107.309% |
| Kamada Ltd. | -46.43 Million USD | 27.793% |
| Indivior PLC | -33.95 Million USD | 1.252% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 12966.595% |
| Flora Growth Corp. | -713 Thousand USD | -4602.244% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -308.195% |
| Evolus, Inc. | 63.7 Million USD | 152.626% |
| HUTCHMED (China) Limited | -197.45 Million USD | 83.021% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 106.998% |
| Akanda Corp. | 3.9 Million USD | 958.584% |